• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

犬尿氨酸作为恶性肿瘤治疗的新靶点。

Kynurenines as a Novel Target for the Treatment of Malignancies.

作者信息

Mor Adrian, Tankiewicz-Kwedlo Anna, Pawlak Dariusz

机构信息

Department of Pharmacodynamics, Medical University of Bialystok, Mickiewicza 2c, 15-222 Bialystok, Poland.

Department of Monitored Pharmacotherapy, Medical University of Bialystok, Mickiewicza 2c, 15-222 Bialystok, Poland.

出版信息

Pharmaceuticals (Basel). 2021 Jun 23;14(7):606. doi: 10.3390/ph14070606.

DOI:10.3390/ph14070606
PMID:34201791
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8308824/
Abstract

Malignancies are unquestionably a significant public health problem. Their effective treatment is still a big challenge for modern medicine. Tumors have developed a wide range of mechanisms to evade an immune and therapeutic response. As a result, there is an unmet clinical need for research on solutions aimed at overcoming this problem. An accumulation of tryptophan metabolites belonging to the kynurenine pathway can enhance neoplastic progression because it causes the suppression of immune system response against cancer cells. They are also involved in the development of the mechanisms responsible for the resistance to antitumor therapy. Kynurenine belongs to the most potent immunosuppressive metabolites of this pathway and has a significant impact on the development of malignancies. This fact prompted researchers to assess whether targeting the enzymes responsible for its synthesis could be an effective therapeutic strategy for various cancers. To date, numerous studies, both preclinical and clinical, have been conducted on this topic, especially regarding the inhibition of indoleamine 2,3-dioxygenase activity and their results can be considered noteworthy. This review gathers and systematizes the knowledge about the role of the kynurenine pathway in neoplastic progression and the findings regarding the usefulness of modulating its activity in anticancer therapy.

摘要

恶性肿瘤无疑是一个重大的公共卫生问题。其有效治疗仍然是现代医学面临的一大挑战。肿瘤已经发展出多种机制来逃避免疫反应和治疗反应。因此,针对克服这一问题的解决方案的研究存在未满足的临床需求。色氨酸代谢产物在犬尿氨酸途径中的积累会增强肿瘤进展,因为它会抑制免疫系统对癌细胞的反应。它们还参与了抗肿瘤治疗耐药机制的形成。犬尿氨酸是该途径中最有效的免疫抑制代谢产物之一,对恶性肿瘤的发展有重大影响。这一事实促使研究人员评估靶向负责其合成的酶是否可能是治疗各种癌症的有效策略。迄今为止,已经针对这一主题进行了大量临床前和临床研究,特别是关于吲哚胺2,3-双加氧酶活性的抑制,其结果值得关注。这篇综述收集并系统整理了关于犬尿氨酸途径在肿瘤进展中的作用的知识,以及调节其活性在抗癌治疗中的有用性的研究结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b68/8308824/8df5a09e566a/pharmaceuticals-14-00606-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b68/8308824/b957a790199f/pharmaceuticals-14-00606-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b68/8308824/3a26e331c897/pharmaceuticals-14-00606-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b68/8308824/8df5a09e566a/pharmaceuticals-14-00606-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b68/8308824/b957a790199f/pharmaceuticals-14-00606-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b68/8308824/3a26e331c897/pharmaceuticals-14-00606-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b68/8308824/8df5a09e566a/pharmaceuticals-14-00606-g003.jpg

相似文献

1
Kynurenines as a Novel Target for the Treatment of Malignancies.犬尿氨酸作为恶性肿瘤治疗的新靶点。
Pharmaceuticals (Basel). 2021 Jun 23;14(7):606. doi: 10.3390/ph14070606.
2
Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway.吲哚胺2,3-双加氧酶-2;犬尿氨酸途径中的一种新酶。
Int J Biochem Cell Biol. 2009 Mar;41(3):467-71. doi: 10.1016/j.biocel.2008.01.005. Epub 2008 Jan 11.
3
The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.靶向吲哚胺2,3-双加氧酶用于癌症治疗的潜力。
Expert Opin Ther Targets. 2015 May;19(5):605-15. doi: 10.1517/14728222.2014.995092. Epub 2015 Feb 15.
4
Tryptophan and kynurenines: continuing to court controversy.色氨酸和犬尿氨酸:持续引发争议。
Clin Sci (Lond). 2016 Aug 1;130(15):1335-7. doi: 10.1042/CS20160294.
5
Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse.免疫激活对小鼠喹啉酸和神经活性犬尿氨酸的影响。
Neuroscience. 1992 Nov;51(1):25-39. doi: 10.1016/0306-4522(92)90467-g.
6
Overview of the role of vitamins and minerals on the kynurenine pathway in health and disease.维生素和矿物质在健康与疾病中对犬尿氨酸途径的作用概述。
J Physiol Pharmacol. 2016 Feb;67(1):3-19.
7
Targeting tryptophan availability to tumors: the answer to immune escape?针对肿瘤色氨酸可用性:免疫逃逸的答案?
Immunol Cell Biol. 2018 Nov;96(10):1026-1034. doi: 10.1111/imcb.12168. Epub 2018 Jun 10.
8
Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib.细胞周期蛋白依赖性激酶抑制剂地西他滨可抑制人类恶性肿瘤中犬尿氨酸途径的激活。
Front Immunol. 2020 Feb 14;11:55. doi: 10.3389/fimmu.2020.00055. eCollection 2020.
9
Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.色氨酸 2,3-双加氧酶活性诱导的肿瘤生长加速及蛋白激酶相关的新型治疗方案。
Adv Exp Med Biol. 2021;1275:339-356. doi: 10.1007/978-3-030-49844-3_13.
10
Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer.血清色氨酸和犬尿氨酸浓度作为子宫内膜癌、卵巢癌和外阴癌患者吲哚胺 2,3-双加氧酶活性的参数。
Int J Gynecol Cancer. 2011 Oct;21(7):1320-7. doi: 10.1097/IGC.0b013e31822017fb.

引用本文的文献

1
SLC7A5 regulates tryptophan uptake and PD‑L1 expression levels via the kynurenine pathway in ovarian cancer.溶质载体家族7成员5(SLC7A5)通过犬尿氨酸途径调节卵巢癌中色氨酸摄取及程序性死亡配体1(PD-L1)表达水平。
Oncol Lett. 2024 Oct 24;29(1):26. doi: 10.3892/ol.2024.14772. eCollection 2025 Jan.
2
Kynurenine Pathway after Kidney Transplantation: Friend or Foe?肾脏移植后的犬尿氨酸途径:是敌是友?
Int J Mol Sci. 2024 Sep 14;25(18):9940. doi: 10.3390/ijms25189940.
3
Kynurenines as a Novel Target for the Treatment of Inflammatory Disorders.犬尿氨酸作为治疗炎症性疾病的新靶点。

本文引用的文献

1
Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1.吲哚胺-2,3-双加氧酶1强效选择性抑制剂BMS-986242的发现及临床前评估
ACS Med Chem Lett. 2021 Jan 28;12(2):288-294. doi: 10.1021/acsmedchemlett.0c00668. eCollection 2021 Feb 11.
2
Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0.使用新型小分子抑制剂 NTRC 3883-0 靶向癌症模型中的吲哚胺 2,3-双加氧酶。
Front Immunol. 2021 Jan 28;11:609490. doi: 10.3389/fimmu.2020.609490. eCollection 2020.
3
GBP1 Facilitates Indoleamine 2,3-Dioxygenase Extracellular Secretion to Promote the Malignant Progression of Lung Cancer.
Cells. 2024 Jul 26;13(15):1259. doi: 10.3390/cells13151259.
4
Aryl hydrocarbon receptor is a tumor promoter in -amplified neuroblastoma cells through suppression of differentiation.芳烃受体通过抑制分化,在扩增的神经母细胞瘤细胞中是一种肿瘤促进因子。
iScience. 2023 Oct 21;26(11):108303. doi: 10.1016/j.isci.2023.108303. eCollection 2023 Nov 17.
5
Association between Expression and Immune Dysregulation in Pancreatic Ductal Adenocarcinoma: Insights from Comprehensive Immune Profiling of Peripheral Blood Mononuclear Cells.胰腺导管腺癌中表达与免疫失调之间的关联:来自外周血单个核细胞综合免疫分析的见解
Cancers (Basel). 2023 Sep 19;15(18):4639. doi: 10.3390/cancers15184639.
6
Adipocyte-derived kynurenine stimulates malignant transformation of mammary epithelial cells through the aryl hydrocarbon receptor.脂肪细胞衍生的犬尿氨酸通过芳香烃受体刺激乳腺上皮细胞的恶性转化。
Biochem Pharmacol. 2023 Oct;216:115763. doi: 10.1016/j.bcp.2023.115763. Epub 2023 Aug 23.
7
Overview of the therapeutic strategies for ER positive breast cancer.ER 阳性乳腺癌的治疗策略概述。
Biochem Pharmacol. 2023 Jun;212:115552. doi: 10.1016/j.bcp.2023.115552. Epub 2023 Apr 15.
8
Kynurenine Pathway in Diabetes Mellitus-Novel Pharmacological Target?犬尿氨酸途径与糖尿病——新的药理学靶点?
Cells. 2023 Jan 31;12(3):460. doi: 10.3390/cells12030460.
9
Targeting cancer-specific metabolic pathways for developing novel cancer therapeutics.靶向癌症特异性代谢途径以开发新型癌症治疗方法。
Front Immunol. 2022 Dec 22;13:955476. doi: 10.3389/fimmu.2022.955476. eCollection 2022.
10
Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.吲哚胺 2,3-双加氧酶 1:恶性肿瘤治疗的新靶点
Front Immunol. 2021 Dec 23;12:800630. doi: 10.3389/fimmu.2021.800630. eCollection 2021.
GBP1促进吲哚胺2,3-双加氧酶的细胞外分泌以促进肺癌的恶性进展。
Front Immunol. 2021 Jan 20;11:622467. doi: 10.3389/fimmu.2020.622467. eCollection 2020.
4
Differential kynurenine pathway metabolism in highly metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression.高转移性侵袭性乳腺癌亚型中差异的犬尿氨酸途径代谢:超越 IDO1 诱导的免疫抑制。
Breast Cancer Res. 2020 Oct 27;22(1):113. doi: 10.1186/s13058-020-01351-1.
5
Trial watch: IDO inhibitors in cancer therapy.试验观察:癌症治疗中的吲哚胺2,3-双加氧酶抑制剂
Oncoimmunology. 2020 Jun 14;9(1):1777625. doi: 10.1080/2162402X.2020.1777625.
6
1-MT inhibits the invasion of CBP-resistant ovarian cancer cells via down-regulating IDO expression and re-activating immune cells function.1-MT 通过下调 IDO 表达和重新激活免疫细胞功能抑制 CBP 耐药卵巢癌细胞的侵袭。
BMC Pharmacol Toxicol. 2020 Sep 11;21(1):67. doi: 10.1186/s40360-020-00439-w.
7
Clinical Significance of Program Death Ligand-1 and Indoleamine-2,3-Dioxygenase Expression in Colorectal Carcinoma.程序性死亡配体-1和吲哚胺-2,3-双加氧酶在结直肠癌中的表达及其临床意义
Appl Immunohistochem Mol Morphol. 2021 Mar 1;29(3):201-208. doi: 10.1097/PAI.0000000000000868.
8
The introduction of immunosuppressor (TDO inhibitor) significantly improved the efficacy of irinotecan in treating hepatocellular carcinoma.免疫抑制剂(TDO 抑制剂)的引入显著提高了伊立替康治疗肝癌的疗效。
Cancer Immunol Immunother. 2021 Feb;70(2):497-508. doi: 10.1007/s00262-020-02697-3. Epub 2020 Aug 25.
9
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.阻断 AHR 可限制由 L-犬尿酸诱导的 Treg-巨噬细胞抑制轴。
Nat Commun. 2020 Aug 11;11(1):4011. doi: 10.1038/s41467-020-17750-z.
10
Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance.黑色素瘤进展和 BRAF 抑制剂耐药中的吲哚胺 2,3-双加氧酶。
Pharmacol Res. 2020 Sep;159:104998. doi: 10.1016/j.phrs.2020.104998. Epub 2020 Jun 11.